For Immediate Release
June 27, 2005

Prostate Cancer: Road Map to the Future

BUFFALO, NY – National experts in prostate cancer will gather for “Prostate Cancer: Road Map to the Future,” hosted by Roswell Park Cancer Institute (RPCI), July 28 – 30, 2005, Niagara Falls Conference Center, 101 Old Falls Street, Niagara Falls, NY, USA.

The program will offer urologists, oncologists, and scientists new information on prostate cancer biology, treatments for advanced prostate cancer and new research in specific biomarkers that may provide a more accurate assessment of the prognosis for prostate cancer. The Prostate Specific Antigen (PSA) serum test, discovered at RPCI by Dr. T. Ming Chu, revolutionized prostate cancer detection and management. Dr. Chu will present a historical perspective on its development.

“Research in prostate cancer is moving forward quickly from understanding how cancer develops through determining how best to treat the disease,” said Donald Trump, MD, Senior Vice President for Clinical Research. “This program gives the urologist and oncologist an opportunity to learn about the latest research findings and new targets for innovative treatments of prostate cancer.”

Invited presenters are:

• Neil Bander, MD, Weill Medical College of Cornell University
• Michael Carey, PhD, UCLA Jonsson Comprehensive Cancer Center
• Andrew Chiarodo, PhD, National Cancer Institute
• T. Ming Chu, Roswell Park Cancer Institute
• Leland Chung, PhD, Emory Healthcare
• Donald Coffey, PhD, Johns Hopkins University School of Medicine
• Yves Fradet, MD, Laval University Cancer Research Center., Quebec, Canada 
• Robert Getzenberg, PhD, Johns Hopkins University School of Medicine
• Norman Greenberg, PhD, Fred Hutchinson Cancer Research Center
• Theresa A. Guise, MD, University of Virginia School of Medicine
• Warren Heston, PhD, The Cleveland Clinic Glicksman Urologic Institute
• John T. Isaacs, PhD, Johns Hopkins University School of Medicine
• Laurence Klotz, MD, FRCSC, Sunnybrook & Women’s College Health Sciences Center
• Hsing-Jien Kung, PhD, University of California Davis School of Medicine
• Hans Lilja, MD, PhD, Memorial Sloan-Kettering Cancer Center
• Alan Partin, MD, PhD, Johns Hopkins University School of Medicine
• Kenneth Pienta, MD, University of Michigan Health System
• Howard I. Scher, MD, Memorial Sloan-Kettering Cancer Center
• Gary Smith, PhD, University of North Carolina at Chapel Hill  
• Donald Trump, MD, FACP, Roswell Park Cancer Institute

RPCI is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians and has designated “Prostate Cancer: Road Map to the Future” a maximum of 13 Category 1 credits toward the American Medical Association (AMA) Physician’s Recognition Award.   

For more information, call (716) 845-3095 or e-mail karen.cooper@roswellpark.org. The complete program may be viewed online at www.roswellpark.org (Go to the Prostate Cancer Conference link).

Roswell Park Cancer Institute, founded in 1898, is the nation’s first cancer research, treatment and education center and is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York.  RPCI is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers.  For more information, visit RPCI’s website at www.roswellpark.org, or call 1-877-ASK-RPCI (1-887-275-7724) or e-mail askrpci@roswellpark.org.

-30-